Sei Investments CO Prothena Corp Public LTD CO Transaction History

Sei Investments CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $112,810 - $168,381	-2,385 Reduced 33.58%	4,717 $227,000
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $52,651 - $85,741	1,091 Added 18.15%	7,102 $484,000
Q1 2023 May 12, 2023	BUY	$46.97 - $58.27 $282,336 - $350,260	6,011 New	6,011 $291,000
Q1 2018 May 11, 2018	SELL	$27.95 - $45.04 $140,588 - $226,551	-5,030 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$35.44 - $63.76 $62,728 - $112,855	1,770 Added 54.29%	5,030 $189,000
Q3 2017 Nov 06, 2017	BUY	$53.83 - $67.75 $175,485 - $220,865	3,260	3,260 $211,000

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.